Revance Therapeutics Inc (RVNC)

[dewophile]

Rvnc has at least phase 2 data in upper limb to support efficacy and guide dosing.
Revance might be able to make an economic argument to insurers in spasticity based on duration.
While CD is a relatively small market if RVNC can show how they can dominate that market it’s not a stretch to argue otjer therapeutic areas will be similar for prospective suitors. There’s more value in that IMO than trying to capture as much off label sales as possible